Encore medical divests non-core US consumer line to Biomedical:
This article was originally published in Clinica
Encore Medical is to sell its Slendertone US consumer business for approximately $6.8m in cash to Bio-Medical Research, the Irish company that developed, manufactures, distributes and owns all intellectual property rights to the Slendertone product line. The transaction, expected to close by the end of June, encompasses the Slendertone inventory and all of Encore's US distribution rights to the products. Proceeds from the sale will be invested into the Austin, Texas company's core surgical implant and orthopaedic rehabilitation businesses. Encore had acquired the US Slendertone unit as part of its acquisition of the electrotherapy company Compex Technologies, which was completed in February 2006 (see Clinica No 1196, p 14).
You may also be interested in...
More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Among the largest gaps in safety data is non-clinical research on CBD use's effect on developing fetus and adolescent brain, in utero/lactational exposure, reproductive toxicity and the potential for a latency period before toxicity, says FDA neuroscientist Andrew Shen.